Background: Recently, newer generation drug-eluting stents (DESs) have been widely adopted in clinical practice. However, there were limited data on safety, performance, and clinical outcomes according to different types of these novel DESs. Methods: A total of 321 patients (pts) who presented with chronic stable angina or acute coronary syndrome treated with Zotarolimus (ZES group; Endeavor ResoluteTM, n=248 pts) and Platinum Chromium (PtCr) based Everolimus (EES group; Promus ElementTM, n=73 pts) -eluting stents were enrolled for this study. Angiographic outcomes at 6 months and cumulative clinical outcomes up to 12 months were compared between the two groups. Results: There were no significant differences in baseline characteristics of patients between 2 groups except that acute myocardial infarction (MI) was more prevalent in ZES group (43.5% vs. 30.1%, p=0.04), especially ST elevation MI, whereas left main (LM) disease were more common in the EES group (2.8% vs. 10.9%, p=0.004). At 6 months, angiographic outcomes including the incidence of binary restenosis and late loss were favorable and similar between the two groups. At 12 months, there was a trend toward higher incidence of non-Q wave MI and stent thrombosis in the EES group. Major clinical outcomes were similar between the two groups at univariate analysis. Further, major clinical outcomes were similar even after adjusting the baseline confounding factors by multivariate analysis (Table). Conclusions: In our study, both new generation DESs, ZES & PtCr based EES were comparable in terms of safety, performance, and clinical outcome at least up to 12 months.